Biotechnology

Bioline RX

Bioline RX released FY2025 9 Months Earnings on November 24 Pre-Market EST with actual revenue of USD 986K and EPS of USD 0.165

Bioline RX released FY2025 Q3 earnings on November 24 Pre-Market EST, actual revenue USD 427 K (forecast USD 670 K), actual EPS USD -0.2244 (forecast USD -0.54)

Bioline RX to Release FY2025 Q3 Earnings on November 24, Pre-Market EST; Forecast Revenue USD 670 K, EPS USD -0.54

Bioline RX released FY2025 Q2 earnings on August 14 Pre-Market EST, actual revenue USD 304 K (forecast USD 661.33 K), actual EPS USD -0.9972 (forecast USD -0.3533)

Bioline RX released FY2025 Semi-Annual Earnings on August 14 Pre-Market EST, actual revenue USD 559 K (forecast USD 870 K), actual EPS USD 0.3102 (forecast USD 1.03)

Bioline RX to Release FY2025 Q2 Earnings on August 14 Pre-Market EST, Forecast Revenue USD 661.33K, EPS USD -0.3533

H.C. Wainwright reiterates buy rating on BioLineRx

Jones Trading Upgrades BioLine Rx Rating to Buy

BioLineRx Achieves Breakthrough in Pancreatic Cancer Clinical Trial

HC Wainwright reiterates Buy rating on BioLine Rx

Bioline RX released FY2025 Q1 earnings on May 27 Pre-Market EST, actual revenue USD 255K (forecast USD 1.481M), actual EPS USD 1.3866 (forecast USD -0.95)

BioLineRX Reports Q1 2025 Revenue Dips to $300,000

BioLine Rx to Report Quarterly Earnings

Bioline RX to release FY2025 Q1 earnings on May 27 Pre-Market EST, forecast revenue USD 1.481 M, EPS USD -0.95

Jones Trading Downgrades BioLine Rx (BLRX.US) Rating to Hold

HC Wainwright & Co. Adjusts BioLine Rx Rating and Target Price

Bioline RX released FY2024 annual earnings on March 31 Pre-Market (EST), actual revenue 28.94 M USD (forecast 24.91 M USD), actual EPS -4.6176 USD (forecast -4.4 USD)

Bioline RX released FY2024 Q4 earnings on March 31 Pre-Market (EST), actual revenue 11.75 M USD (forecast 7.718 M USD), actual EPS -1.4616 USD (forecast -1.6 USD)

Bioline RX to Release FY2024 Annual Earnings on March 31, Pre-Market EST; Forecast Revenue: 24.91 M USD, EPS: -4.4 USD

Bioline RX released FY2024 Q3 earnings on November 25 Pre-Market (EST), actual revenue 4.943 M USD (forecast 5.29 M USD), actual EPS -2.9118 USD (forecast -2.8 USD)

Treasure Gbl

SMX Security Matters

Wheeler Real Estate

DigitalBridge

Toro

Dreamland

Lichen

Springview

Alumis

Top Kingwin

Adma Biologics

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel Pharma

OpGen

Vertex Pharma

Regeneron Pharma

Alnylam Pharma

Argenx

Beigene

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap